39 completed, 20 unknown, 7 terminated, 1 active not recruiting. 70 Phase 2, 27 Phase 1, 10 Phase 3.
Follow Chronic Limb-Threatening Ischemia: new trials by email Literature Review of Chronic Limb-Threatening Ischemia trials Research Report on Chronic Limb-Threatening Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg, - Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia | Phase 2 | Recruiting | Aplagon Oy | 42 | 2026-01-29 | 2026-04-09 |
| Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease Etribnabdione 25 mg BID, Etribnabdione 50 mg BID - Peripheral Arterial Disease | Phase 2 | Not yet recruiting | VivaCell Biotechnology España | 30 | 2026-01-01 | 2025-09-17 |
| TP03HN106 in Patients With Critical Limb Ischemia TP03HN106 - Critical Limb Ischemia | Phase 2 | Completed | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | 15 | 2024-07-18 | 2026-09-30 |
| YQ23 Study in Patients With Critical Limb Ischaemia YQ23, Matching placebo - Critical Limb Ischemia | Phase 1 / Phase 2 | Terminated | New Beta Innovation Limited | 5 | 2021-03-10 | 2023-12-08 |
| Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial), Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial) - Critical Limb Ischemia | Phase 1 / Phase 2 | Completed | S.Biomedics Co., Ltd. | 20 | 2020-11-04 | 2024-08-30 |
| Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia. Autologous ASC (for Adipose-derived Stem/Stroma Cell) - Critical Limb Ischemia and Peripheral Artery Disease | Phase 2 | Terminated | University Hospital, Toulouse | 2 | 2020-03-04 | 2023-03-31 |
| Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers AMG0001, Placebo - Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease | Phase 2 | Unknown | AnGes USA, Inc. | 60 | 2020-01-30 | 2021-12-22 |
| Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction Rejuveinix Low Dose, Rejuveinix High Dose - Critical Limb Ischemia, Peripheral Arterial Disease | Phase 1 / Phase 2 | Unknown | Reven Pharmaceuticals, Inc. | 320 | 2020-01-01 | 2018-08-09 |
| Cell Therapy in Critical Limb Ischemia allogeneic umbilical cord-derived mesenchymal stem cells, Placebo (NaCl) - Critical Limb Ischemia | Phase 2 | Unknown | CHU de Reims | 30 | 2019-09-01 | 2019-06-21 |
| Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia Cell-based therapy - Chronic Limb-threatening Ischemia, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | 24 | 2019-01-01 | 2022-11-30 |
| Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs Allogeneic Mesenchymal Stromal Cell, Placebo - Peripheral Arterial Disease, Cardiovascular Diseases | Phase 2 / Phase 3 | Unknown | Martin Teraa, MD, PhD | 60 | 2018-12-01 | 2018-05-03 |
| Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI) CardioCell, Placebos - Critical Limb Ischemia | Phase 2 / Phase 3 | Unknown | John Paul II Hospital, Krakow | 50 | 2018-04-19 | 2021-04-09 |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) CLBS12, SOC - Critical Limb Ischemia, Buerger Disease | Phase 2 | Completed | Lisata Therapeutics, Inc. | 33 | 2017-11-01 | 2024-10-09 |
| Autologous BMMNC Combined With HA Therapy for PAOD RV-P1501 - Peripheral Arterial Occlusive Disease, Critical Limb Ischemia | Phase 1 / Phase 2 | Withdrawn | Academia Sinica, Taiwan | 2017-01-17 | 2022-03-15 | |
| An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK) Ranger SL DEB - Lower Limb Ischemia, Peripheral Vascular Diseases | Phase 2 / Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2016-11-01 | 2018-05-18 |
| Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia ADRC injection, ADRC isolation, Liposuction - Critical Limb Ischemia, Arteriosclerosis Obliterans | Phase 1 / Phase 2 | Unknown | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 9 | 2016-07-01 | 2016-08-12 |
| BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) BGC101 (autologous EnEPC preparation), Control medium - Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | Phase 1 / Phase 2 | Active not recruiting | BioGenCell Ltd. | 40 | 2016-06-01 | 2025-06-06 |
| Plerixafor in Diabetic Wound Healing Plerixafor, Placebo - Diabetes, Wounds | Phase 2 | Terminated | Gian Paolo Fadini | 25 | 2016-06-01 | 2019-12-19 |
| Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia rivaroxaban plus aspirin, clopidogrel plus aspirin - Critical Limb Ischemia | Phase 2 | Completed | Ottawa Hospital Research Institute | 20 | 2014-10-01 | 2019-12-04 |
| To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI Autologous Stromal Vascular Fraction (SVF), Autologous Adipose Derieved MSCs, Control - Critical Limb Ischemia | Phase 1 / Phase 2 | Unknown | Kasiak Research Pvt. Ltd. | 60 | 2014-08-01 | 2014-05-23 |
Showing 20 of 70. Sign in to see all of them.
Peripheral Vascular Diseases (23) · Peripheral Arterial Disease (21) · Arterial Occlusive Diseases (7) · Ischemia (6) · Diabetic Foot (5) · Peripheral Arterial Occlusive Disease 1 (5) · Thromboangiitis Obliterans (5) · Diabetes Mellitus (4) · Vascular Diseases (4) · Intermittent Claudication (2) · Leg Ulcer (2) · Ulcer (2) · Arteriosclerosis Obliterans (1) · Cardiovascular Diseases (1)
Arteriosclerosis (70) · Atherosclerosis (70) · Chronic Disease (70) · Disease Attributes (70) · Pathologic Processes (70) · Pathological Conditions, Signs and Symptoms (70) · Cardiovascular Diseases (69) · Vascular Diseases (66) · Ischemia (64) · Arterial Occlusive Diseases (63) · Peripheral Arterial Disease (49) · Peripheral Vascular Diseases (47) · Endocrine System Diseases (10) · Diabetes Mellitus (6) · Skin Diseases (6)
Standard of Care (4) · Saline Solution (3) · Aspirin (2) · Cell- and Tissue-Based Therapy (2) · Sodium Chloride (2) · treprostinil (2) · BID protein, human (1) · Clopidogrel (1) · Drug Therapy (1) · Granulocyte Colony-Stimulating Factor (1) · HBOC 201 (1) · Heparin (1) · Hydroxyethyl Starch Derivatives (1) · Injections (1) · Laser-Doppler Flowmetry (1)
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (5) · AnGes USA, Inc. (4) · Flanders Medical Research Program (2) · Stempeutics Research Pvt Ltd (2) · Academia Sinica, Taiwan (1) · Aldagen (1) · Apceth GmbH & Co. KG (1) · Aplagon Oy (1) · Asklepios Kliniken Hamburg GmbH (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Northland Biotech. Co., Ltd. (1) · Beike Biotech India Pvt.ltd (1) · BioGenCell Ltd. (1) · Biopure Corporation (1) · CHU de Reims (1)
United States (19) · India (7) · Spain (6) · Germany (5) · China (4) · France (4) · Netherlands (4) · Italy (3) · South Korea (3) · Belgium (2) · Canada (2) · Israel (2) · Russia (2) · Colombia (1) · Finland (1)
Antonio Chacon, MD, PhD (2) · Diego Martinez, MD, PhD (2) · Inmaculada Herrera, MD, PhD (2) · Marc Bosiers, MD (2) · Marianne C Verhaar, MD, PhD (2) · Richard Powell, MD (2) · A. Gerson Greenburg, MD, Ph.D. (1) · Alexander Reyzelman, MD (1) · Alisha Oropallo, MD (1) · Andreas M Zeiher, MD (1) · Andres Garcia, MD, PhD (1) · Andrey A Kalinin, MD, PhD (1) · Andrey A Pulin, MD, PhD (1) · Anthony J Comerota, MD (1) · Antonio De la Cuesta, MD (1)
PMID 35802393, PMID 37740111, PMID 18559703, PMID 19700099, PMID 20529449, PMID 21146749, PMID 21205939, PMID 21586692, PMID 21594960, PMID 21684715, PMID 22079876, PMID 22169682, PMID 22284892, PMID 22453769, PMID 23192920, PMID 23758736, PMID 24218170, PMID 25567765, PMID 26148006, PMID 26428987, PMID 26526721, PMID 26861113, PMID 28351310, PMID 28411244, PMID 29242062, PMID 30004916, PMID 33144352, PMID 34538132, PMID 37626416, PMID 41186002
2009 (2), 2005 (1), 2008 (1), 2025 (1)